SCHEMBL23930240

SCHEMBL23930240

CCOC(=O)c1c(F)cnc(Cl)c1F

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JMJD6 Q6NYC1 1/20 0.41
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CA7 P43166 1/20 0.41
CA9 Q16790 1/20 0.41
CA14 Q9ULX7 1/20 0.41
NR1H2 P55055 1/20 0.40
NR1H3 Q13133 1/20 0.40
PDE4B Q07343 1/20 0.40
ALDH1A1 P00352 4/20 0.40
NPSR1 Q6W5P4 4/20 0.40
NPC1 O15118 3/20 0.40
MAPT P10636 3/20 0.40
TP53 P04637 2/20 0.40
HSD17B10 Q99714 2/20 0.40
XBP1 P17861 1/20 0.40
MAPK1 P28482 1/20 0.40
HTT P42858 1/20 0.40
TLR9 Q9NR96 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30007197 1.00 JMJD6 (0.41) JMJD6CA12CA1CA2CA7
SCHEMBL24337507 0.85 ALDH1A1 (0.42) JMJD6CA12CA1CA2CA7
SCHEMBL31305819 0.82 CA12 (0.36) CA12CA1CA2CA7CA9
SCHEMBL31297236 0.81 HTT (0.41) JMJD6CA12CA1CA2CA7
SCHEMBL20638918 0.81 HTT (0.41) JMJD6CA12CA1CA2CA7
SCHEMBL30562749 0.80 HTT (0.40) JMJD6CA12CA1CA2CA7
SCHEMBL25388657 0.80 HTT (0.40) JMJD6CA12CA1CA2CA7
SCHEMBL20639130 0.79 KDM4E (0.50) JMJD6CA12CA1CA2CA7
SCHEMBL22717775 0.78 KMT2A (0.51) JMJD6ALDH1A1NPC1MAPTTP53
SCHEMBL31049055 0.78 KMT2A (0.51) JMJD6ALDH1A1NPC1MAPTTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230203004-A1 RSV INHIBITING 3-SUBSTITUTED QUINOLINE AND CINNOLINE DERIVATIVES JANSSEN PHARMACEUTICA NV (BE) 2023-06-29 US disclosed
US-20230203004-A1 RSV INHIBITING 3-SUBSTITUTED QUINOLINE AND CINNOLINE DERIVATIVES JANSSEN PHARMACEUTICA NV (BE) 2023-06-29 US disclosed
EP-4139293-A1 RSV INHIBITING 3-SUBSTITUTED QUINOLINE AND CINNOLINE DERIVATIVES Janssen Sciences Ireland Unlimited Company (IE) 2023-03-01 EP disclosed
CN-115461336-A RSV inhibiting 3-substituted quinoline and cinnoline derivatives 爱尔兰詹森科学公司 2022-12-09 CN disclosed
WO-2021214136-A1 RSV INHIBITING 3-SUBSTITUTED QUINOLINE AND CINNOLINE DERIVATIVES Janssen Sciences Ireland Unlimited Company (IE) 2021-10-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230203004-A1 RSV INHIBITING 3-SUBSTITUTED QUINOLINE AND CINNOLINE DERIVATIVES ACE2, SIRT7, ACE JMJD6 4724/4885CA12 2834/4885CA1 4415/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.